Lexicon Pharmaceuticals, Inc.
NASDAQ:LXRXBiotechnology
-$0.05 today
- Market cap
- $765.80M
- Beta
- 1.07
- P/E (TTM)
- -30.5
- EPS (TTM)
- -$0.07
Volume 2.02M
Average 2.48M
LXRX Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Lexicon Pharmaceuticals, Inc.NASDAQ: LXRX
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $110K fell 37.5% year over year, behind the -1.9% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 6.8% from the prior quarter. Over 3 fiscal years it compounded at +13.3% a year.
Context
- Depreciation & amortization amounted to 1.2% of revenue in FY2025, down 0.5 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -37.5% toward the trailing-twelve-month pace of -1.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 621K USD
- Year-over-year change
- +16.3%
- 4-year CAGR
- +20.8%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 621K | +16.3% |
| FY2024 | 2024-12-31 | 534K | -3.6% |
| FY2023 | 2023-12-31 | 554K | +29.7% |
| FY2022 | 2022-12-31 | 427K | +46.2% |
| FY2021 | 2021-12-31 | 292K | — |
Depreciation & Amortization vs competitors
How LXRX compares with its peers on the latest reported figures
- LXRX's LTM Mar 2026 depreciation & amortization of $555K is the 7th highest of the 11 companies compared; the peer median is $1.8M.
- Its year-over-year change of -1.9% is the 8th highest of 11, against a peer median of +2.9%.
- Depreciation & amortization amounts to 0.8% of revenue for LXRX, versus a peer median of 2.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $55.3M | +97.1% | -33.0% | 5.5% | |
| LTM Sep 2026 | $21.89M | +6.2% | +0.9% | 2.3% | |
| LTM Mar 2026 | $17.02M | +70.2% | +24.9% | 4.7% | |
| LTM Jun 2026 | $5.95M | +365.1% | -1.1% | 0.6% | |
| LTM Mar 2026 | $2.41M | -1.0% | +34.3% | 0.8% | |
| LTM Mar 2026 | $1.19M | +3.5% | +8.1% | — | |
| LTM Mar 2026 | $555K | -1.9% | +13.3% | 0.8% | |
| LTM Mar 2026 | $167K | -73.0% | -39.9% | 2.3% | |
| LTM Sep 2026 | $140K | -7.3% | +49.6% | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $59K | -90.6% | -29.5% | — |
| LTM Mar 2026 | $43K | +2.4% | +19.8% | — | |
| Peer median (excluding LXRX) | $1.8M | +2.9% | +4.5% | 2.3% | |
Competitors are the stored peer set for LXRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 298K | 139K | 1.2M | 31.08M | 49.8M |
| Cost of Revenue | 55.05M | 52.52M | 58.97M | 616K | 274K |
| Gross Profit | (54.75M) | (52.38M) | (57.77M) | 30.47M | 49.53M |
| Gross Margin | -18371.8% | -37681.3% | -4798.0% | 98.0% | 99.4% |
| Research & Development | 55.05M | 52.82M | 58.89M | 84.48M | 61.12M |
| Selling, General & Admin | 0 | 0 | 0 | 131.9M | 37.32M |
| Operating Expenses | 32.34M | 48.38M | 113.98M | 227.58M | 98.44M |
| Depreciation & Amortization | 292K | 427K | 554K | 534K | 621K |
| EBITDA | (86.66M) | (100.03M) | (169.76M) | (184.29M) | (41.38M) |
| EBITDA Margin | -29081.9% | -71966.2% | -14099.3% | -592.9% | -83.1% |
| Operating Income | (87.09M) | (100.76M) | (171.75M) | (197.12M) | (48.91M) |
| Operating Margin | -29224.8% | -72489.2% | -14265.0% | -634.2% | -98.2% |
| Interest Income | 134K | 1.6M | 7.73M | 12.29M | 6.91M |
| Interest Expense | 802K | 2.78M | 13.1M | 15.58M | 8.34M |
| Other Income / Expenses | (668K) | (1.18M) | (5.37M) | (3.29M) | (1.43M) |
| Income Before Tax | (87.76M) | (101.94M) | (177.12M) | (200.4M) | (50.34M) |
| Pre-Tax Margin | -29449.0% | -73341.0% | -14710.9% | -644.8% | -101.1% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (87.76M) | (101.94M) | (177.12M) | (200.4M) | (50.34M) |
| Net Margin | -29449.0% | -73341.0% | -14710.9% | -644.8% | -101.1% |
| EPS (Basic) | (0.61) | (0.62) | (0.80) | (0.63) | (0.14) |
| EPS (Diluted) | (0.61) | (0.62) | (0.80) | (0.63) | (0.14) |
| Weighted Avg Shares | 145.65M | 165.73M | 221.13M | 320.03M | 363.05M |
| Weighted Avg Shares (Diluted) | 145.65M | 165.73M | 221.13M | 320.03M | 363.05M |
Lexicon Pharmaceuticals, Inc.
NASDAQ:LXRX
Intrinsic Alpha fair value
Locked
Current Price
$1.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.